Skip to main content
Download PDF
Download ePub

Correction to: The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer

Journal of Experimental & Clinical Cancer Research volume 40, Article number: 7 (2021) Cite this article

The Original Article was published on 17 October 2020

Correction to: J Exp Clin Cancer Res (2020) 39:219

https://0-doi-org.brum.beds.ac.uk/10.1186/s13046-020-01728-2

Following the publication of the original article [1], it was noted that the representative images of Rad51 immunofluorescence staining of H82 cell line in the original Figure 5A of this article were presented incorrectly. The errors occurred because the representative images of H526 were not appropriately labeled for H82 by error during the figure preparation. The updated Figure 5A was generated and is shown below based on the original raw data. The authors declare that these corrections do not change the results or conclusions of this paper. The authors apologize for this error.

The original article has been corrected.

figure a

Reference

  1. Ma L, et al. The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer. J Exp Clin Cancer Res. 2020;39:219.

    Article  CAS  Google Scholar 

Download references

Author information

Author notes

  1. Liying Ma and Xing Bian contributed equally to this work.

Authors and Affiliations

  1. High Magnetic Field Laboratory, Chinese Academy of Sciences, Hefei, 230031, Anhui, P. R. China

    Liying Ma, Xing Bian & Wenchu Lin

  2. University of Science and Technology of China, Hefei, 230026, Anhui, P. R. China

    Liying Ma & Xing Bian

  3. Key Laboratory of High Magnetic Field and Ion Beam Physical Biology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, 230031, Anhui, P. R. China

    Liying Ma, Xing Bian & Wenchu Lin

Authors
  1. Liying Ma
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xing Bian
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Wenchu Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Wenchu Lin.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ma, L., Bian, X. & Lin, W. Correction to: The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer. J Exp Clin Cancer Res 40, 7 (2021). https://0-doi-org.brum.beds.ac.uk/10.1186/s13046-020-01805-6

Download citation

  • Published:

  • DOI: https://0-doi-org.brum.beds.ac.uk/10.1186/s13046-020-01805-6

Journal of Experimental & Clinical Cancer Research

ISSN: 1756-9966

Contact us